Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$565M |
| 2 |
Shopify
SHOP
|
+$376M |
| 3 |
Alibaba
BABA
|
+$289M |
| 4 |
NovoCure
NVCR
|
+$170M |
| 5 |
Spotify
SPOT
|
+$164M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
C.H. Robinson
CHRW
|
+$393M |
| 2 |
Under Armour
UAA
|
+$311M |
| 3 |
Amazon
AMZN
|
+$213M |
| 4 |
Stellantis
STLA
|
+$203M |
| 5 |
Meta Platforms (Facebook)
META
|
+$190M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 33.91% |
| 2 | Communication Services | 17.09% |
| 3 | Healthcare | 16.31% |
| 4 | Financials | 10.01% |
| 5 | Technology | 9.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Apple
AAPL
$4.56T
| $26.5M | 0.03% |
557,388
+37,344
| +7% | +$1.58M |
|
152
American Express
AXP
$235B
| $25.9M | 0.03% |
236,838
-2,351
| -1% | -$247K |
|
153
Ameren
AEE
$29.9B
| $25.7M | 0.03% |
349,085
+11,049
| +3% | +$770K |
|
154
Galicia Financial Group
GGAL
$7.73B
| $25.3M | 0.03% |
991,541
-2,292
| -0.2% | -$71.8K |
|
|
AGR
155
DELISTED
Avangrid, Inc.
AGR
| $24.3M | 0.03% |
483,214
+27,625
| +6% | +$1.36M |
|
156
Banco Macro
BMA
$5.66B
| $24.2M | 0.03% |
528,133
+29,234
| +6% | +$1.5M |
|
157
HEICO Corp
HEI
$51.5B
| $23.1M | 0.03% |
244,021
-3,989
| -2% | -$348K |
|
|
ZUO
158
DELISTED
Zuora, Inc.
ZUO
| $21.6M | 0.02% |
+1,076,132
| New | +$23.2M |
|
159
Axogen
AXGN
$2.43B
| $20.7M | 0.02% |
980,700
+343,900
| +54% | +$6.28M |
|
|
JT
160
DELISTED
Jianpu Technology Inc. American Depositary Shares, each representing twenty Class A Ordinary Shares
JT
| $19.4M | 0.02% |
483,990
+19,025
| +4% | +$890K |
|
161
Stratasys
SSYS
$783M
| $19.2M | 0.02% |
805,117
+45,226
| +6% | +$1.09M |
|
162
Veeco
VECO
$3.29B
| $17.7M | 0.02% |
1,634,793
+116,207
| +8% | +$1.2M |
|
163
Cullen/Frost Bankers
CFR
$10.3B
| $17.2M | 0.02% |
177,208
+18,307
| +12% | +$1.82M |
|
|
FARO
164
DELISTED
Faro Technologies
FARO
| $17.1M | 0.02% |
389,286
+34,301
| +10% | +$1.51M |
|
165
Ambarella
AMBA
$3.7B
| $17M | 0.02% |
394,410
+17,047
| +5% | +$674K |
|
|
ORTX
166
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $16.5M | 0.02% |
92,500
| – | – |
|
|
ADAP
167
DELISTED
Adaptimmune Therapeutics
ADAP
| $16.5M | 0.02% |
3,839,190
+139,669
| +4% | +$650K |
|
168
Lindblad Expeditions
LIND
$2.25B
| $16.4M | 0.02% |
1,072,701
| – | – |
|
169
Digimarc Corp
DMRC
$168M
| $16.2M | 0.02% |
517,714
+39,894
| +8% | +$989K |
|
170
Dolby
DLB
$5.79B
| $15.5M | 0.02% |
245,708
+11,831
| +5% | +$756K |
|
|
VAR
171
DELISTED
Varian Medical Systems, Inc.
VAR
| $15.4M | 0.02% |
108,904
| – | – |
|
|
KDNY
172
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $15.2M | 0.02% |
766,285
+34,050
| +5% | +$594K |
|
173
M&T Bank
MTB
$36.4B
| $15.2M | 0.02% |
96,766
| – | – |
|
174
Johnson & Johnson
JNJ
$616B
| $14.4M | 0.02% |
103,146
+8,280
| +9% | +$1.11M |
|
|
NCNA
175
NuCana
NCNA
$5.49M
| $14.1M | 0.02% |
165
| – | – |
|
Similar funds
Baillie Gifford & Co's Q1 2019 Portfolio in Review
As of Q1 2019, Baillie Gifford & Co held 236 positions worth $91.4B, up 19% from $77B the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Baillie Gifford & Co's Q1 2019 filing shows 10 new, 116 increased, 68 reduced and 9 closed positions. Its largest new stake was Vale: 10,553,700 shares worth $138M. The largest sale was C.H. Robinson, an estimated $393M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 34% of assets, up from 34% a quarter earlier, followed by Communication Services and Healthcare.
- Baillie Gifford & Co's largest Q1 2019 buy was Vale: 10,553,700 shares worth $138M.
- Baillie Gifford & Co added most to Microsoft in Q1 2019, an estimated $565M increase.
- Baillie Gifford & Co's biggest Q1 2019 reduction was C.H. Robinson, cutting an estimated $393M.
- Baillie Gifford & Co fully exited Under Armour in Q1 2019, selling an estimated $311M.
- Baillie Gifford & Co's ten largest holdings make up 45% of its $91.4B portfolio in Q1 2019.
- Baillie Gifford & Co opened 10 new positions and closed 9 in Q1 2019.
- Baillie Gifford & Co's portfolio value rose 19% quarter-over-quarter to $91.4B.
Based on Baillie Gifford & Co's 13F filing for Q1 2019, filed 1 May 2019.